Mitigating Chemotherapy-Induced Myelosuppression in ES-SCLC: An Expert Roadmap for Optimizing Clinical and Patient-Reported Outcomes

This educational session, which was recorded during our Grand Rounds series conducted in 2025-2026 with Dr. Martin Dietrich, affords learners a timely and succinct overview of the rapidly evolving ES-SCLC treatment landscape, with a keen focus on the best practice mitigation and management of chemotherapy-induced myelosuppression (CIM), a major challenge in ES-SCLC care. More specifically, Dr. Dietrich dives into practical pearls of proactive strategies for achieving multilineage myeloprotection in patients living with ES-SCLC, and in so doing, not only improving their clinical outcomes, but also their quality-of-life.To access the slides, the bibliography, and our Cornerstone Clinical Tool for this activity, please visit our website here: https://cornerstonemeded.com/educational-programs/_es-sclc/.